Share Twitter LinkedIn Facebook Email PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Hossein Borghaei, MD discusses the recent data released and advantages and potential limitations of the new drug. Advertisement
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read